{'fraction_non_alphanumeric': 0.01943198804185351, 'fraction_numerical': 0.012705530642750373, 'mean_word_length': 5.114155251141552, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[A clinical assessment of a 3 month replacement therapy effectiveness with low norethisterone acetate (Activelle) in postmenopausal women].

AIM
The clinical evaluation of Activelle formula in treatment of climacteric symptoms in postmenopausal women.


MATERIAL AND METHODS
Formula Activelle (oral 1 mg 17 beta-estradiol combined with 0.5 mg norethisterone acetate) was applied daily in 100 post-menopausal women during 3 months. The control group consisted of 20 women. Initially and at the 3rd month body mass, body mass index, systolic and diastolic blood pressure, AspAT and AIAT levels as well as total cholesterol, triglycerides, FSH and 17 beta-estradiol levels were measured. Green scale was used to assess the severity of menopausal symptoms.


RESULTS
Mean FSH levels decreased and mean estradiol level increased in plasma significantly in women who were given Activelle formula. Only vasomotoric group of symptoms in Green scale was reduced after 3 month therapy in women who had activelle administered. No significant change was found in regard to other parameters.


CONCLUSION
Formula Activelle seems to be efficient in removal of vasomotoric menopausal symptoms after 3 month of therapy. The administration of Activelle formula enables to reach the serum estradiol level which is sufficient in prophylaxis of osteoporosis.